Free Trial
ETR:BIO

Biotest Aktiengesellschaft (BIO) Stock Price, News & Analysis

Biotest Aktiengesellschaft logo
€41.40 0.00 (0.00%)
(As of 11/20/2024 ET)

About Biotest Aktiengesellschaft Stock (ETR:BIO)

Key Stats

Today's Range
€41.40
€41.40
50-Day Range
€41.40
€42.40
52-Week Range
€40.40
€43.40
Volume
N/A
Average Volume
1,927 shs
Market Capitalization
$819.31 million
P/E Ratio
9.98
Dividend Yield
0.10%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A.

Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biotest Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

BIO Stock News Headlines

Biotest Aktiengesellschaft (BIESF)
[625,000% Gain] – Are You Ready for the Next Altcoin Boom?
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Biotest Aktiengesellschaft (BIO3.F)
Biotest Aktiengesellschaft (BIO3.SW)
Biotest Aktiengesellschaft (BIO3D.XC)
Biotest Aktiengesellschaft (BIOD.XC)
See More Headlines

BIO Stock Analysis - Frequently Asked Questions

Biotest Aktiengesellschaft's stock was trading at €42.60 at the beginning of the year. Since then, BIO shares have decreased by 2.8% and is now trading at €41.40.
View the best growth stocks for 2024 here
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biotest Aktiengesellschaft investors own include GSK (GSK), Invitae (NVTA), Adaptive Biotechnologies (ADPT), ADMA Biologics (ADMA), Analog Devices (ADI), Adaptimmune Therapeutics (ADAP) and Axcelis Technologies (ACLS).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Measuring And Control Equipment
CIK
N/A
Fax
N/A
Employees
8,200
Year Founded
N/A

Profitability

Net Income
$164.40 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$781.30 million
Cash Flow
€1.33 per share
Book Value
€13.26 per share

Miscellaneous

Free Float
N/A
Market Cap
$819.31 million
Optionable
Not Optionable
Beta
0.24
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (ETR:BIO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners